Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2011

Mar 31, 2011

291_ip_2011-03-31_d9e79ee9-226e-440c-8f1d-39a30b03b1bd.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

BioCapital Europe 2011

Amsterdam – March 31, 2011

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions regulatory reforms foreign exchange rate fluctuations and the conditions, reforms, the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Morp y hoS s at a Glance

Industry y 's most successful antibody library technology - HuCAL

75 drug programs ongoing

P fit bl t b l h t Profitable, strong balance sheet

Use proprietary technologies to develop the broadest possible pipeline of therapeutic antibody drugs,

balanced between partnered and proprietary programs

Growing p Pi eline Illustrates Successful Execution of Strategy

Clinical Total

Uniq p y gy ue & Proprietary Technology for Generating Drug-Quality Antibodies

75 Th ti A tib d P O i Therapeutic ntibody Programs Ongo ing

MOR103A Novel Anti-Inflammatory Antibody

The Target

GM-CSF – a growth factor and inflammatory mediator

The Drug

Ultra-high affinity HuCAL IgG1

Clinical Development in Rheumatoid Arthritis

  • Phase 1b/2a trial ongoing in Europe in patients with active RA
  • Completion of enrollment H2 2011 final results H1 2012 2011,

Clinical Development in Multiple Sclerosis

Phase 1b safety study in MS patients starting H2 2011

Intellectual Property

  • Exclusive license to a US patent covering antibodies against GM-CSF for the treatment of chronic inflammatory conditions
  • US patent on MOR103 composition of matter

MOR208A Novel Anti-Cancer Antibody

The Target

CD19 – a pan B-cell marker p 30 Namalwa

The Drug

  • Humanized, high affinity anti-CD19 antibody
  • Exclusive license from Xencor
  • Comprises a proprietary Xencor modification that leads to rapid and sustained B-cell depletion

Clinical Development in Chronic Lymphocytic Leukemia

  • Multi-centre, open-label, multi-dose, single-arm phase 1, dose-escalation study in USA Lymphoma
  • Patients with chronic lymphocytic leukemia, who have not responded to or have become refractory to previous therapies
  • Xencor funds phase 1 trial from \$13m up front payment up-front
  • Final data expected in 2012

MOR208

XmAb (-) control

Alemtuzumab (CD52)

MOR202A Novel Antibody for Multiple Myeloma

The Target

CD38 – a protein on multiple myeloma cells

The Drug

  • High affinity HuCAL antibody
  • Excellent cross-reactivity to non-human primate (tox)

Clinical Development in Multiple Myeloma

  • Start multi-centre, open-label, dose-escalation study in Europe H1 2011
  • Patients with relapsed/refractory multiple myeloma; failure of at least 2 prior therapies
  • Maximum tolerated dose, safety and tolerability, pharmacokinetics and immunogenicity; assessment of preliminary activity
  • Final data expected in 2013

Partnered Programs Phase 2 Clinical Development

P
r
o
g
r
a
m		 P
t
a
r
n
e
r		 D
i
s
e
a
s
e		 T
t
a
r
g
e		 S
t
t
a
u
s
Q
B
H
8
8
0		 N
i
t
o
v
a
r
s		 O
l
i
t
t
s
e
o
y
c
b
d
i
o
n
e
s
e
a
s
e		 D
K
K
1
-		 E
l
d
h
i
l
i
f
b
t
t
t
a
r
y
a
a
s
o
w
s
m
u
a
o
n
o
o
n
e
f
i
t
o
r
m
a
o
n
d
n		 N
i
t
o
v
a
r
s		 d
n		 d
n		 C
l
i
i
l
f
f
h
i
d
t
n
c
a
p
r
o
o
o
c
o
n
c
e
p
a
c
e
v
e
C
N
T
O
8
8
8		 C
O
h
t
t
e
n
o
c
o
r
r
o
B
i
h
t
o
e
c		 O
l
n
c
o
o
g
y		 M
C
P
1
-		 T
i
l
i
t
o
r
a
s
o
n
g
o
n
g
w
C
N
T
O
8
8
8		 C
O
h
t
t
e
n
o
c
o
r
r
o
B
i
h
t
o
e
c		 I
d
i
h
i
t
o
p
a
c
l
p
m
o
n
a
r
u
y
f
i
b
i
r
o
s
s		 M
C
P
1
-		 O
i
l
i
t
n
e
r
a
o
n
g
o
n
g
G
b
t
a
n
e
n
e
r
m
a
u		 R
h
o
c
e		 '
's
A
A
l
l
h
h
i
i
z
e
m
e
r
d
i
s
e
a
s
e		 A
l
i
d
β
m
o
y
-		 S
d
i
i
i
h
d
l
A
D
t
t
t
t
n
p
a
e
n
s
p
r
o
r
o
m
a
u
y
w

Partnered Programs Phase 1 Clinical Development

P
r
o
g
r
a
m		 P
t
a
r
n
e
r		 D
i
s
e
a
s
e		 S
t
t
a
u
s
C
N
T
O
1
9
5
9		 C
O
h
B
i
h
t
t
t
e
n
o
c
o
r
r
o
o
e
c		 P
i
i
s
o
r
a
s
s		 S
d
l
d
Q
4
2
0
1
0
t
t
c
o
m
p
e
e
u
y
B
A
Y
9
4
6
2
0
7
-		 B
H
l
h
t
a
y
e
r
e
a
c
a
r
e		 O
l
n
c
o
o
g
y		 C
A
i
b
d
d
j
A
I
X
t
t
n
o
y
r
u
g
c
o
n
u
g
a
e
v
s
-
C
O
N
T
3
1
5
7		 C
O
O
h
h
B
B
i
i
h
h
t
t
t
e
n
o
c
o
r
r
o
o
e
c		 A
h
t
s
m
a		 P
P
h
h
1
1
J
J
2
0
1
0
t
t
a
s
e
s
a
r
n
e
u
d
n		 N
i
t
o
a
r
s
v		 M
l
k
l
l
t
s
c
o
s
e
e
a
u
u		 P
h
J
l
1
2
0
1
0
t
t
a
s
e
s
a
r
u
y
d.
n		 N
i
t
o
v
a
r
s		 O
h
h
l
l
t
p
a
m
o
o
g
y		 P
h
1
A
2
0
1
0
t
t
t
a
s
e
s
a
r
u
g
u
s
d
n		 N
i
t
o
a
r
s
v		 I
f
l
i
t
n
a
m
m
a
o
n		 P
h
D
b
1
2
0
1
0
t
t
a
s
e
s
a
r
e
c
e
m
e
r
d
d
n		 C
C
t
t
e
n
o
c
o
r		 I
f
l
i
/
t
n
a
m
m
a
o
n
A
i
t
o
m
m
n
e
u
u		 P
P
h
h
1
1
D
D
b
b
2
0
1
0
t
t
t
t
a
s
e
s
a
r
e
c
e
m
e
r
d
n		 B
h
i
I
l
h
i
o
e
r
n
g
e
r
n
g
e
e
m		 d
n		 P
h
1
D
b
2
0
1
0
t
t
a
s
e
s
a
r
e
c
e
m
e
r
d
n		 P
f
i
e
r
z		 O
l
n
c
o
o
g
y		 P
h
D
b
1
2
0
1
0
t
t
a
s
e
s
a
r
e
c
e
m
e
r
O
M
P
9
R
5
5
-		 O
d
n
c
o
m
e		 O
l
n
c
o
o
g
y		 P
h
1
D
b
2
0
1
0
t
t
a
s
e
s
a
r
e
c
e
m
e
r

AbD Serotec Seg p ment Complements Therapeutic Business

Antibodies for research and diagnostic markets

Diagnostic Antibodies

  • Using proprietary technologies to deliver superior Dx antibodies
  • Future upside via royalties

Research Antibodies

  • Catalogue of 15,000+ products & custom HuCAL antibodies
  • Stable and recurring cash flows
E
U
R
i
l
l
i
m
o
n
s		 G
i
d
2
0
1
1
u
a
n
c
e		 2
0
1
0
S
S
A
b
D
R
t
t
e
r
o
e
c
e
g
m
e
n
e
e
n
e
s
v
u		 2
2
2
3
-		 2
0
2.
S
A
b
D
P
f
i
M
i
t
t
e
r
o
e
c
r
o
a
r
g
n		 4
%
~		 6
%
E
U
R
i
l
l
i
m
o
n
s		 2
0
0
9		 2
0
1
0		 G
i
d
u
e 2
a
n
c
0
1
1		 S
T
k
t
r
e
a
s
u
r
y
o
c
0.
4
%
B
d
o
a
r
2
%
R
e
e
n
e
s
v
u		 8
1.
0		 8
7.
0		 1
0
5
1
1
0
–
C
f
G
S
d
l
d
t
o
s
o
o
o
s
o		 6.
7		 3
7.
P
i
R
&
D
E
t
r
o
p
r
e
a
r
p.
y
x		 1
9.
3		 2
6.
5		 4
0
4
5
–
S
d
R
&
D
E
p
o
n
s
o
r
e
x
p.		 1
9.
7		 2
0.
4
S
G
&
A
E
x
p
e
n
s
e
s
,		 2
3.
9		 2
3.
2
T
l
O
i
E
t
t
o
a
p
e
r
a
n
g
p.
x		 6
9.
6		 4
7
7.
i
O
h
O
t
t
e
r
p
e
r
a
n
g
I
n
c
o
m
e		 0.
1		 0.
2
P
f
i
f
t
r
o
r
o
m
O
i
t
p
e
r
a
o
n
s		 1
1.
4		 9.
8		 1
0
1
3
–

Cash & Marketable Securities (31/12/10): € 108.4m

Shares issued: 22,890,252 (Dec 31, 2010) ( )

A Rich Potential News-flow in 2011

H1 2011

  • US patent granted on MOR103 9
  • Double digit EUR million technology milestone payment received from N ti9Novartis MOR103
  • Commence Phase 1 study of MOR202 in multiple myeloma
  • Release MOR202 pre-clinical data
  • New partner INDs
  • First diagnostic kit based on a HuCAL antibody comes to market
  • Further technology announcements New partner INDs gy

H2 2011

  • Complete enrollment in MOR103 Phase 1b/2a RA study
  • Commence Phase 1b MS study of
  • Clinical data from trial of CNTO888 in oncology*
  • Clinical data from trial of CNTO1959 in psoriasis*

  • Clinical data from trial of CNTO3157 in asthma*

  • New deal(s) based on Slonomics technology

* MorphoSys estimates only

Thank You

www.morphosys.com

Dr. Claudia Gutjahr-Löser

Head of Corporate Comm. & IR

Phone +49 ( ) 0 89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →